Страна: Армения
Язык: английский
Источник: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
fluconazole
Fareva Amboise
fluconazole
50mg
capsules
Prescription
1. NAMEOF THE MEDICINAL PRODUCT DIFLUCAN ® 50 mg, capsules DIFLUCAN ® 150 mg, capsules DIFLUCAN ® 2 mg/ml, solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Active substance: fluconazole DIFLUCAN capsules 50 mg and 150 mg contains active ingredient respectively 5 mg and 150 mg. The solution for infusion represents 2 mg/ml in a saline solution. For the full list of excipients, please refer to section 6.1. 3. PHARMACEUTICAL FORM Capsule, solution for intravenous infusion. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. Fluconazole is indicated to treat the following diseases in adults: - cryptococcal meningitis; - coccidioidomycosis; - invasive candidiasis; - mucosal candidiasis, including oropharyngeal candidiasis, oesophageal candidiasis, candiduria and chronic mucocutaneous candidiasis; - chronic oral atrophic candidiasis (associated with dentures) with insufficient observation of oral hygiene or local treatment; - acute and recurrent vaginal candidiasis if local treatment is not administered; - candidal balanitis if local treatment is not administered; - dermatomycoses, including tinea pedis, tinea corporis, tinea cruris, pityriasis versicolor and candida infections of the skin if systemic treatment is indicated; - nail infection (onychomycosis) if no treatment with other medicinal products has been administered. Fluconazole is indicated for prophylaxis of the following diseases in adults: - relapse of cryptococcal meningitis in patients with a high risk of relapse; - relapse of oropharyngeal candidiasis and oesophageal candidiasis in HIV-positive patients with a high risk of relapse; - to reduce the incidence of recurrent vaginal candidiasis (four or more episodes per year); - to prevent candida infections in patients with prolonged neutropenia (for instance haemoblastoma patients who are Прочитать полный документ